K-G-D-S
CAS No. 93674-95-4
K-G-D-S( ——— )
Catalog No. M41790 CAS No. 93674-95-4
KGDS is synthetic peptides, targeting integrin GPIIb-IIIa located on the membrane of human activated platelets. Amino acid sequence: Lys-Gly-Asp-Ser.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 371 | In Stock |
|
| 10MG | 543 | In Stock |
|
| 25MG | Get Quote | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameK-G-D-S
-
NoteResearch use only, not for human use.
-
Brief DescriptionKGDS is synthetic peptides, targeting integrin GPIIb-IIIa located on the membrane of human activated platelets. Amino acid sequence: Lys-Gly-Asp-Ser.
-
DescriptionKGDS is synthetic peptides, targeting integrin GPIIb-IIIa located on the membrane of human activated platelets. Amino acid sequence: Lys-Gly-Asp-Ser.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number93674-95-4
-
Formula Weight405.41
-
Molecular FormulaC15H27N5O8
-
Purity>98% (HPLC)
-
SolubilityH2O : ≥ 200 mg/mL (493.34 mM)
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Luo, W., et al. Construction and in vitro studies of magnetic-apoferritin nanocages conjugated with KGDS peptide targeted at activated platelets for the MRI diagnosis of thrombus. J Nanopart Res 21, 177 (2019).
molnova catalog
related products
-
3-Morpholino-1-(4-(2...
3-Morpholino-1-(4-(2-oxopiperidin-1-yl)phenyl)-5,6-dihydropyridin-2(1H)-one shows antitumor activity in a human colon cancer cell line and may be used to combat thrombosis.
-
Phenazoline
Argireline a synthetic peptide which is patterned from the N-terminal end of the protein SNAP-25 can both reduce the degree of existing facial wrinkles and demonstrate effectively against their development.
-
Porcine dynorphin A(...
Porcine dynorphin A (1-13) is a potent, endogenous κ opioid receptor agonist and is antinociceptive at physiological concentrations. Exposure to dynorphin A (1-13) causes acute increases in [Ca2+]i in individual neurons similar to increases seen with acute NMDA treatment.
Cart
sales@molnova.com